BIOVIE INC

BIVI stock represents ownership in BioVie Inc., a clinical-stage biopharmaceutical company. The ticker trades on the Nasdaq Capital Market under the symbol BIVI. Because it is a small-cap biotech with no approved products generating revenue, its stock is closely tied to pipeline developments and clinical trial outcomes rather than commercial sales.

Recent performance for BIVI depends on clinical trial updates, financing news, and broader biotech sentiment, so the price can move sharply over short periods. For the latest price change, volume, and percentage moves, refer to the current BIVI quote and performance data displayed on this page.

BIVI is sensitive to clinical trial results, regulatory decisions from the FDA, and the company's ability to fund ongoing research. Scientific setbacks, safety concerns, or delays can pressure the stock, while positive data readouts or partnership announcements can support it. Broader biotech market conditions and small-cap liquidity also influence BIVI's share price.

Shares of BIVI can be purchased through a brokerage account that offers Nasdaq-listed securities. Many online brokers allow you to place market or limit orders during regular trading hours. Before buying, confirm any commissions, minimums, or eligibility requirements, and verify that your broker supports trading in small-cap biotech stocks.

Valuation for a clinical-stage company like BIVI often relies on cash position, pipeline potential, and risk-adjusted expectations rather than traditional earnings multiples. Because BioVie may not have consistent profits, metrics such as price-to-book, enterprise value, and cash runway can be more informative. Compare these figures with similar biotech peers to gauge relative valuation.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, BIVI may also face limited liquidity, high price volatility, and dependence on key personnel or partnerships. Competitive therapies and changes in healthcare policy can further affect the company's prospects.